COMP <GO>
TGTX vs MRK // RSI-14 & 200D SMA MOMENTUM
TG Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: TGTX 7
— MRK 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: TGTX
LAST: $61.18 (+5.34%) • MKT CAP: $8.89B
rsi-technicals
69.7
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
rsi-technicals
56.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TGTX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TGTX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.70% | 74.80% | +8.90 | TGTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.00% | 20.70% | -8.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.3x | 15.3x | +58.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | -0.28% | 3.42% | -3.70 | MRK | /fcf-yield <GO> |
| Operating Margin | 20.00% | 34.30% | -14.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.10% | +39.90 | TGTX | /net-margins <GO> |
| Revenue Growth (YoY) | 87.30% | 1.30% | +86.00 | TGTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.92 | 5.19 | +7.73 | TGTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.60% | -0.10 | TGTX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 69.7 | 56.9 | +12.85 | TGTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.92 | -0.05 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.7x | 18.4x | -1.70 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.89B | $361.02B | -$352.13B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TGTX REV | MRK REV | TGTX GROSS % | MRK GROSS % | TGTX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $616.3M | $65.01B | 83.7% | 74.8% | -$25.0M | $12.36B |
| FY 2024 | $329.0M | $64.17B | 88.3% | 76.3% | -$40.6M | $18.10B |
| FY 2023 | $233.7M | $60.12B | 44.0% | 44.0% | -$41.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TGTX // BETA 0.87
MRK // BETA 0.92